Uremia-Induced Gut Barrier Defect in 5/6 Nephrectomized Mice Is Worsened by Candida Administration through a Synergy of Uremic Toxin, Lipopolysaccharide, and (1➔3)-β-D-Glucan, but Is Attenuated by Lacticaseibacillus rhamnosus L34

A chronic kidney disease (CKD) causes uremic toxin accumulation and gut dysbiosis, which further induces gut leakage and worsening CKD. Lipopolysaccharide (LPS) of Gram-negative bacteria and (1➔3)-β-D-glucan (BG) of fungi are the two most abundant gut microbial molecules. Due to limited data on the impact of intestinal fungi in CKD mouse models, the influences of gut fungi and Lacticaseibacillus rhamnosus L34 (L34) on CKD were investigated using oral C. albicans-administered 5/6 nephrectomy (5/6Nx) mice. At 16 weeks post-5/6Nx, Candida-5/6Nx mice demonstrated an increase in proteinuria, serum BG, serum cytokines (tumor necrotic factor-α; TNF-α and interleukin-6), alanine transaminase (ALT), and level of fecal dysbiosis (Proteobacteria on fecal microbiome) when compared to non-Candida-5/6Nx. However, serum creatinine, renal fibrosis, or gut barrier defect (FITC-dextran assay and endotoxemia) remained comparable between Candida- versus non-Candida-5/6Nx. The probiotics L34 attenuated several parameters in Candida-5/6Nx mice, including fecal dysbiosis (Proteobacteria and Bacteroides), gut leakage (fluorescein isothiocyanate (FITC)-dextran), gut-derived uremic toxin (trimethylamine-N-oxide; TMAO) and indoxyl sulfate; IS), cytokines, and ALT. In vitro, IS combined with LPS with or without BG enhanced the injury on Caco-2 enterocytes (transepithelial electrical resistance and FITC-dextran permeability) and bone marrow-derived macrophages (supernatant cytokines (TNF-α and interleukin-1 β; IL-1β) and inflammatory genes (TNF-α, IL-1β, aryl hydrocarbon receptor, and nuclear factor-κB)), compared with non-IS activation. These injuries were attenuated by the probiotics condition media. In conclusion, Candida administration worsens kidney damage in 5/6Nx mice through systemic inflammation, partly from gut dysbiosis-induced uremic toxins, which were attenuated by the probiotics. The additive effects on cell injury from uremic toxin (IS) and microbial molecules (LPS and BG) on enterocytes and macrophages might be an important underlying mechanism.


Introduction
Chronic kidney disease (CKD) has been recognized as an extensive worldwide burden for decades [1], causing an accumulation of various metabolic chemicals known as "uremic toxins". Such toxins mainly derived from food components or metabolic activities in the body can contribute to various complications, such as cardiovascular diseases, pulmonary problems, and CKD progression [2]. Some circulating uremic toxins are formed in the GI tract, known as gut-derived uremic toxins [3], including trimethylamine-N-oxide (TMAO), indoxyl sulfate, p-cresol sulfate, hippuric acid, and phenylacetic acid [4]. Because of the defect of toxin elimination through kidneys in advanced CKD, the accumulated toxins are compensatorily excreted into the intestinal tract and selectively promote the overgrowth of pathogenic intestinal bacteria, so-called gut dysbiosis [5]. Dysbiosis enhances the production of gut-derived uremic toxins. The toxins (gut and non-gut derivatives) can impair intestinal epithelial tight junctions, which lead to translocation of microbial molecules from the gut into blood circulation, so-called gut leakage or gut translocation [6]. Although the intestine is a source of gut-derived uremic toxins, the toxins distribute throughout the body (including the intestine) induce damage to several cells, including enterocytes and renal tubules [7][8][9]. The vicious cycle that CKD causes uremic toxin accumulation and gut dysbiosis, which further induces gut leakage and worsens CKD, is referred to as the gut-kidney axis [10]. Gut translocation of microbial molecules and uremic toxins facilitates the inflammatory reaction and accelerate CKD progression [11].
Among microbial molecules in the gut, lipopolysaccharide (LPS) of Gram-negative bacteria and (1→3)-β-D-glucan (BG) of fungi are the two most abundant molecules in the gut [10]. However, the impact of intestinal fungi in mouse models is underappreciated, as Candida albicans is less abundant in the mouse gut than in the human intestine [12]. The amount of Candida spp. in mouse feces is insufficient to be detectable in stool culture [12], which differs from the that of human feces [13]. Although gut fungi do not directly cause illness, they affect the gut microbiota and supply BG in the gut [14], contributing to the worsening of systemic inflammation following gut barrier defect (gut leakage). Candida administration in bilateral nephrectomy (acute kidney injury) mice induces more severe gut leakage and inflammatory responses [11]. However, there are still very few investigations on the impact of gut fungi on uremic disorders, and a CKD model with C. albicans presentation has never been explored. Because gut microbiota plays a major role in regulating the production of gut-derived uremic toxins and the toxins as well as endotoxemia worsen CKD progression [15,16], the use of probiotics might prevent gut dysbiosis, reduce the toxin, and delay CKD progression [17][18][19]. Lacticaseibacillus rhamnosus L34 (L34), a strain of intestinal flora isolated from the Asian population [20], improves gut permeability integrity in several animal models of acute illnesses [21]. Due to (i) the worsening renal fibrosis and CKD progression by systemic inflammation [22], (ii) systemic inflammation-induced gut leakage in acute uremia model [11], and (iii) the anti-inflammatory properties of probiotics [21,23,24], L34 administration might also help delay the CKD progression in the Candida-administered CKD mice.
Here, we explored the impact of C. albicans and L34 on renal histopathology, CKD progression, inflammatory markers, and gut leakage in the Candida-administered 5/6 nephrectomy (5/6Nx) mouse model. To understand the pathophysiologic effects of fungi on CKD, BG (the main fungal cell wall component) was used in vitro with LPS (a major component of Gram-negative bacterial cell wall) and indoxyl sulfate (a representative gut-derived uremic toxin) on enterocytes (Caco-2 cells) and macrophages (bone marrowderived cells). During 16 weeks of the observation, there was no mortality in 5/6Nx mice with or without Candida administration (data not shown). Chronic kidney disease (CKD) char-acteristics in 5/6Nx mice, compared with sham, was demonstrated by retardation of weight gain, increase in urine volume and proteinuria, increase in serum creatinine, presence of anemia, and gut barrier defect determined by endotoxemia, increased serum BG, and FITC-dextran assay, as early as 8 weeks after surgery ( Figure 1A-H). In comparison with 5/6Nx mice without Candida, Candida-administered 5/6Nx mice had more prominent FITC-dextran (at 8 weeks), more proteinuria, and higher serum BG (glucanemia) (at 16 weeks) ( Figure 1C,G,H). Among all of the time-point parameters, only proteinuria in Candida-5/6Nx mice demonstrated the worsening level at 16 weeks compared with 8 weeks (Figure 1C), supporting the CKD disease progression [25].

An Additive Effect of Indoxyl Sulfate, a Uremic Toxin, on Enterocytes and Macrophages Was Attenuated by Lacticaseibacillus Condition Media
Gut-derived uremic toxins frequently tested with indoxyl sulfate (IS) [47], can induce proinflammatory responses [48], which further enhance CKD progression [7,49]. With activation by a single molecule, the viability of enterocytes (Caco-2) reduced with 10 mM indoxyl sulfate or 400 μg/mL LPS (alone), but not BG alone ( Figure 5A), implying the limited toxicity of BG on enterocytes. However, BG with IS (as low as 0.5 mM) reduced enterocyte viability ( Figure 5A) supported an effect of the uremic toxin on enterocyte injury. Although the cell viability in the combined incubation of IS with LPS or LPS plus BG (LPS + BG) was comparable, such viability was higher than in the IS + BG combination ( Figure 5A).

An Additive Effect of Indoxyl Sulfate, a Uremic Toxin, on Enterocytes and Macrophages Was Attenuated by Lacticaseibacillus Condition Media
Gut-derived uremic toxins frequently tested with indoxyl sulfate (IS) [47], can induce proinflammatory responses [48], which further enhance CKD progression [7,49]. With activation by a single molecule, the viability of enterocytes (Caco-2) reduced with 10 mM indoxyl sulfate or 400 µg/mL LPS (alone), but not BG alone ( Figure 5A), implying the limited toxicity of BG on enterocytes. However, BG with IS (as low as 0.5 mM) reduced enterocyte viability ( Figure 5A) supported an effect of the uremic toxin on enterocyte injury. Although the cell viability in the combined incubation of IS with LPS or LPS plus BG (LPS + BG) was comparable, such viability was higher than in the IS + BG combination ( Figure 5A). concentrations (100 and 300 μg/mL) did not reduce the viability of Caco-2 cells and TEER (data not shown).  The effects of IS were also demonstrated by reduced transepithelial electrical resistance (TEER) and enhanced enterocyte permeability (FITC-dextran) when compared with the incubation by pathogen molecules alone ( Figure 5B,C). The gut leakage was higher in the LPS + BG, compared to the activation by each molecule alone, and was highest in the LPS + BG with IS ( Figure 5B,C). Lacticaseibacillus condition media (LCM) attenuated such injury from either LPS + BG or LPS + BG + IS; however, was higher than the control non-stimulated condition ( Figure 5B,C). Of note, LPS at the lower concentrations (100 and 300 µg/mL) did not reduce the viability of Caco-2 cells and TEER (data not shown).
Because of the importance of macrophages in recognizing pathogen molecules [50,51], bone marrow-derived cells were used in the experiments. As such, IS alone (≥2 mM) or with LPS (or BG) reduced macrophage viability, and the combination between IS with LPS or BG did not reduce the toxic concentration of IS ( Figure 6A). Although LPS + BG did not increase macrophage inflammation, indicated by supernatant cytokines (TNF-α and IL-1β), and the expression of inflammatory genes (TNF-α, IL-1β, aryl hydrocarbon receptor, and NF-κB), when compared to the LPS alone, which suggested the enhanced responses of IS against LPS, BG, and LPS + BG (Figures 6 and 7). In comparison with LPS + BG, the Lacticaseibacillus condition media-treated group (LCM + LPS + BG) attenuated these parameters, although not reaching the level of the control groups (Figures 6 and 7). These data supported the impact of gut fungi and uremic toxins on intestinal barrier defects and systemic inflammation.

Gut Candida Altered Chronic Kidney Disease (CKD) in 5/6Nx Mice through Gut Dysbiosis, Intestinal Barrier Defect, and Systemic Inflammation
C. albicans in mouse feces is detectable only by PCR [52], not by culture [12], which differs from human conditions [13], Candida was orally administered in 5/6Nx mice to examine the impact of gut fungi in CKD. Candida-5/6Nx mice had more severe gut leakage (FITC-dextran at 8 weeks post-surgery) with higher serum BG (glucanemia) that possibly worsened proteinuria and liver damage (alanine transaminase (ALT)), and increased serum cytokines compared to 5/6Nx mice. Although Candida did not alter CKD severity determined by serum creatinine and kidney fibrosis, higher serum BG in Candida-5/6Nx mice enhanced responses against endotoxemia [7,53] that induced proteinuria and high ALT [26,27]. Although fungi were nondetectable in the feces of non-Candida 5/6Nx mice (data not shown), the detectable serum BG in these mice supported the role of BG from mouse chow in gut contents [54]. While Candida gavage in acute kidney injury (AKI) enhances gut leakage-induced inflammation and mortality [11], systemic inflammation from gut-Candida in CKD is not severe enough to increase the mortality partly due to the different compensation in acute versus chronic uremia [55]. An impact of acute uremia on enterocytes might be more potent than chronic uremia with a better adaptation to the cell micro-environments [55].
Uremia-induced gut dysbiosis is a result of an increase in intestinal excretion of the accumulated uremic toxins that promote the growth of gut pathogenic bacteria, increase gutderived uremic toxins, and enhance systemic inflammation. These effects exert injury on renal vascular endothelium [56,57] and parenchymal cells [58,59] that causes a vicious cycle of uremic toxins induced gut dysbiosis, and the dysbiosis further enhanced CKD progression through the higher toxin accumulation. Then, this vicious cycle is possibly facilitated by gut fungi due to the enhanced serum BG with the presence of Candida in the gut. Interestingly, spontaneous glucanemia and endotoxemia (without systemic infection) in patients with CKD support the CKD-induced gut barrier defect [60] that might be correlated with gut dysbiosis. Indeed, gut fungi in 5/6Nx mice facilitated pathogenic Proteobacteria without alteration on Bacteroides and Firmicutes compared with non-Candida 5/6Nx. The gavage of Candida (live or heat-killed) in other mouse models facilitates fecal pathogenic bacteria [30,31,61], perhaps due to the BG fermentation properties of some bacteria [62]. Here, Candida also enhanced the growth of Helicobacter spp. and Allobaculum spp. that might be associated with uremic gastritis and mucus degradation [32,33]. Therefore, further exploration of gut fungi in CKD is interesting.

Lacticaseibacillus rhamnosus L34 (L34) Attenuated Candida-Administered 5/6Nx Mice through the Anti-Inflammatory Effect on Enterocytes and Macrophages
The attenuation of uremic enteropathy (gut dysbiosis and gut leakage) and gut-derived uremic toxins by L34 has been demonstrated [11]. However, the effect of L34 on the CKD model with Candida administration has never been explored. Despite a more profound inflammation in Candida-5/6Nx than non-Candida 5/6Nx, L34 attenuated disease severity in these mice, as indicated by renal injury (improve renal fibrosis and proteinuria, but not serum creatinine), gut barrier defect (FITC-dextran, but not LPS and BG), gut-derived uremic toxins (TMAO and IS), systemic inflammation (serum cytokines), and liver damage (ALT). Notably, serum creatinine has a limitation as a CKD biomarker [63] and has a higher molecular weight (MW) than 4.4 kDa of FITC-dextran. The MW of pathogen molecules (LPS and BG) [10] also varies. Therefore, after probiotic treatment, serum creatinine, LPS, and BG might be unchanged. In parallel, L34 improved gut dysbiosis as demonstrated by a reduction of the possible pathogenic bacteria (Bacteroides, Proteobacteria, and Helicobacter spp.) [11,32] with an increase in Clostridium spp. (the possible beneficial Fermenters) [64]. However, L34 increased Cyanobacteria (toxin-producing bacteria) [41] and Allobaculum spp. (bacteria with both advantage and disadvantage properties [32,33]). Although L34 did not alter Firmicutes (the high abundant bacteria in healthy condition) in the microbiome analysis ( Figure 3A), LEfSe indicated several bacteria in the Firmicutes group in L34-treated mice ( Figure 3E). As gut dysbiosis [5], gut leakage [6,7], gut-derived uremic toxins [6,65], and inflammatory cytokines are enhanced in advanced CKD, attenuation of these mechanisms might retard the CKD progression [11]. Our findings support such effects of probiotics on retardation of CKD progression.
In addition, the impact of indoxyl sulfate (IS), a representative gut-derived uremic toxin, on enterocytes and macrophages was evaluated in vitro using the extract of L34 in culture media. Indoxyl sulfate is a water-soluble form of indoxyl, a molecule converted from tryptophan amino acid by gut bacteria in the luminal side of the intestines [47] and is metabolized into IS by the liver and contacts the basolateral part of the enterocytes through blood circulation [9]. IS promotes the production of reactive oxygen species that directly induce cell damage and cell death in several organs [66,67]. Despite the resistance of Caco-2 against IS (reduced cell viability at 10 mM of IS), IS as low concentration as 0.5-1 mM could induce intestinal cell death [9] and enterocyte permeability (TEER and FITC-dextran assay) when combined with LPS or BG. These results imply an impact of IS on enterocytes during CKD-induced uremic intestine [68]. In parallel, macrophages were more susceptible to IS as the cell viability reduced in IS at 2 mM, but the combination of IS with LPS or BG did not decrease the IS concentration. Without IS, BG alone did not induce macrophage responses, and BG with LPS demonstrated the tendency of the additive proinflammatory effect but was not different from LPS activation alone. With IS, the additive proinflammatory effect was increased as IS + LPS + BG induced a higher level of inflammatory cytokines than IS + LPS. The additive effect is possibly due to the similar downstream signaling through the NFκB transcription factor of TLR-4 and Dectin-1, the pattern recognition receptors of LPS and BG, respectively, and aryl hydrocarbon receptor (the cytosolic receptor of IS) [69] as demonstrated in the working hypothesis figure (Figure 8). Despite the profound inflammation from combined IS with LPS and BG, LCM attenuated both enterocyte permeability defect and macrophage inflammation. These findings support the benefits of probiotics on CKD [70], possibly through anti-inflammatory exopolysaccharide [71]. Although the MW of IS, at 0.23 kDa, is small enough to pass through the normal intestinal tight junction (MW lower than 0.6 kDa) [10,72], several probiotics decrease serum IS [73,74], implying a decrease in bacteria with IS production property during advanced CKD. Probiotic tests on other CKD models might be interesting because of the possible difference in interference of gut dysbiosis and inflammatory responses in individual CKD models. For example, gut dysbiosis might be more prominent in the oral adenine-induced CKD model due to its direct effect on intestinal microbiota with inflammasome-related inflammatory mechanisms (crystal-mediated inflammation) [75][76][77][78]. With gut dysbiosis attenuation and the anti-inflammatory properties of the probiotics, further exploration in other CKD models and clinical studies for a potential application in CKD are warranted.

Animals
Animal care and experiments were performed according to the National Institutes of Health (NIH) criteria [79] using the approved protocol by the Institutional Animal Care and Use Committee of the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (CU-ACUP No. 018/2562). Eight-week-old male C57BL/6 mice were purchased from Nomura Siam (Pathumwan, Bangkok, Thailand).

Animals
Animal care and experiments were performed according to the National Institutes of Health (NIH) criteria [79] using the approved protocol by the Institutional Animal Care and Use Committee of the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (CU-ACUP No. 018/2562). Eight-week-old male C57BL/6 mice were purchased from Nomura Siam (Pathumwan, Bangkok, Thailand).

Candida-Administered 5/6 Nephrectomy Model and the Probiotics
The 5/6 nephrectomy (5/6 Nx) surgery was performed via flank approach under isoflurane anesthesia. The upper and lower poles of the left kidney were removed, and a right nephrectomy was performed one week later. Only mice with a weight of the removed fragments from the left kidney to the right kidney weight in a ratio of 0.55-0.72 were included to ascertain that removal of the left kidney mass is optimum for the CKD development [25]. Then, the 5/6Nx mice were divided into 3 groups, including the phosphate buffer solution (PBS) control (5/6Nx PBS), Candida-administered 5/6Nx (5/6Nx + Candida), and 5/6Nx + Candida with the probiotic administration (5/6Nx + Candida + L34). As such, Candida albicans from the American Type Culture Collection (ATCC 90028) (Fisher Scientific, Waltham, MA, USA) were cultured overnight on Sabouraud dextrose broth (SDB) (Oxoid, Hampshire, UK) at 35 • C for 48 h before enumeration using a hemocytometer. C. albicans at 1 × 10 6 CFU in a 0.5 mL PBS or PBS alone was orally administered on alternate days starting from 4 weeks after the right kidney removal of the 5/6Nx procedure. For the probiotics, Lacticaseibacillus rhamnosus L34 (L34) from the stock (Chulalongkorn University) was cultured on deMan-Rogosa-Sharpe (MRS) agar (Oxoid™, Hampshire, UK) under anaerobic conditions (10% CO 2 , 10% H 2 , and 80% N 2 ) using gas generation sachets (AnaeroPack ® -Anaero; Mitsubishi Gas Chemical, Tokyo, Japan) at 37 • C for 48 h before use. After 4 weeks of the right nephrectomy, L34 at 1 × 10 7 colony-forming unit (CFU) in 0.25 mL PBS were orally administered 3 times a week (on the different days of C. albicans gavage) until 16 weeks post-5/6Nx. Another group of mice was the sham operation to identify renal vessels before abdominal closure (Sham group). The L34-administered 5/6Nx mice without Candida have not been demonstrated here because the benefits of L34 on non-Candida-administered mice with uremia are previously published [11].

Gut Permeability Determination
Gut permeability was determined by fluorescein isothiocyanate dextran (FITC-dextran) assay and the spontaneous elevation of LPS as well as BG in blood [23,[82][83][84]. The detection of FITC-dextran (an intestinal nonabsorbable molecule) in serum at 3 h after an oral administration or spontaneous serum elevation of endotoxin without systemic inflammation indicates gut permeability defect (gut leakage) [23,[82][83][84]. In the FITC-dextran assay, 12.5 mg of FITC-dextran (4.4 kDa) (FD4; Sigma-Aldrich ® , St. Louis, MO, USA) was orally administered. At 3 h thereafter, FITC-dextran in serum was measured from blood samples by Fluorospectrometer (NanoDrop™ 3300; Thermo Fisher Scientific™, Wilmington, DE, USA). Serum LPS (endotoxin) and BG was evaluated by HEK-Blue LPS Detection Kit 2 (In-vivoGen™, San Diego, CA, USA) and Fungitell ® assay (Associates of Cape Cod, Falmouth, MA, USA), respectively. Due to the lower limit of the standard curve of the test, the value less than 0.01 EU/mL and 7.8 pg/mL in LPS and BG assay, respectively, were recorded as 0.

Fecal Microbiome Analysis
Feces (0.25 g per mouse) were collected from the mice in different cages per group to avoid the influence of allocoprophagy (a habit of ingesting the feces from other mice) and fecal microbiome analysis was performed as previously described [39]. The metagenomic DNA was extracted from the prepared samples using a DNAeasy Kit (Qiagen, Hilden, Germany) with DNA quality assessment using Nanodrop spectrophotometry. Universal prokaryotic primers 515F (5 -GTGCCAGCMGCCGCGGTAA-3 ) and 806R (5 -GGACTACHVGGGT WTCTAAT-3 ) with appended 50 Illumina adapters and 30 Golay barcode sequences were used for 16S rRNA gene V4 library construction.

In Vitro Experiments
To test a possible effect of BG (a major Candida component) on intestine and systemic inflammation, indoxyl sulfate was used as a representative gut-derived uremic toxin on enterocytes (Caco-2) (American Type Culture Collection, Manassas, VA, USA) and bone marrow-derived macrophages. Macrophages were derived from the bone marrow of 8 week-old mice using the modified Dulbecco's Modified Eagle's Medium (DMEM) and conditioned media of the L929 cell line (a source of macrophage colony-stimulating factor) as previously mentioned [85]. The Caco-2 (at 2 × 10 6 cells/well) or bone marrowderived macrophages (BMDM) (at 5 × 10 4 cells/well) in DMEM were incubated with the different concentrations of indoxyl sulfate (Sigma-Aldrich) alone or together with BG (CM-Pachyman) (Megazyme, Bray, Ireland) at 100 µg/mL with or without LPS (Escherichia coli O26:B6) (Sigma-Aldrich) at 400 µg/mL (for Caco-2 cells) and 100 µg/mL (for macrophages) before the determination of cell viability with tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) solution [86]. The 24 h-activated cells were incubated with 0.5 mg/mL of MTT solution (Thermo Fisher Scientific) for 2 h at 37 • C in the dark, and MTT was removed and diluted with dimethyl sulfoxide (DMSO; Thermo Fisher Scientific) before measurement with a Varioskan Flash microplate reader at an absorbance of optical density at 570 nm. The different concentrations of LPS in Caco-2 and macrophages are due to the variable LPS resistance between these cells [87].
Additionally, the 24 h stimulated Caco-2 cells were used to evaluate the integrity of intestinal cells as determined by transepithelial electrical resistance (TEER) [88]. To establish the confluent monolayer, Caco-2 cells at 5 × 10 4 cells per well were seeded onto the upper compartment of 24-well Boyden chamber trans-well, using DMEM-high glucose supplemented with 20% Fetal Bovine Serum (FBS), 1% HEPES, 1% sodium pyruvate, and 1.3% Penicillin/Streptomycin for 15 days. TEER, in ohm (Ω) × cm 2 , was measured with an epithelial volt-ohm meter (EVOM2™, World precision instruments, Sarasota, FL, USA) by placing electrodes in the supernatant at the basolateral chamber and in the apical chamber. The TEER values in media culture without Caco-2 cells were used as a blank and were subtracted from all other measurements. In parallel, the enterocyte permeability was also evaluated by the FITC-dextran test following the published protocols [89]. As such, 5 µL of FITC-dextran (4.4 kDa) (Sigma-Aldrich) at 10 mg/mL was added to the apical side of the trans-well chamber with 24 h stimulated Caco-2 cells, and the FITC-dextran from the basolateral side of the trans-well plate was measured at 1 h after incubation using a Fluorospectrometer (NanoDrop 3300) (ThermoFisher Scientific). The concentration of FITC-dextran from the basolateral side, in percentage relative to the dose on the apical side, represents the severity of permeability defect of Caco-2 cells.

Statistical Analysis
Analyzed data are presented as mean ± standard error (SE) using GraphPad Prism version 9.0 software (La Jolla, CA, USA). Statistical significance was determined by one-way analysis of variance (ANOVA) followed by Tukey's analysis or Student's t-test for comparisons among groups and between the 2 groups, respectively. The time-point experiments were analyzed by the repeated measures ANOVA. All statistical analyses were performed with Stata 16.0 software (StataCorp, TX, USA) and Graph Pad Prism version 7.0 software (La Jolla, CA, USA). The p-value of <0.05 was considered statistically significant.

Conclusions
Candida administration enhanced leaky gut and inflammatory responses in 5/6Nx CKD mice through the additive inflammatory activation of IS with LPS and BG. L. rhamnosus L34 attenuated the severity of Candida-5/6Nx mice, partly through the improved enterocyte integrity and the induced anti-inflammatory macrophages. Some probiotics would be an important adjuvant therapy in patients with CKD in the near future.

Institutional Review Board Statement:
The study was conducted in accordance with the National Institutes of Health (NIH) criteria, and the animal study protocol was approved by the Institutional Animal Care and Use Committee of the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (CU-ACUP No. 018/2562). Data Availability Statement: Not applicable.

Conflicts of Interest:
The authors declare no conflict of interest.